TP53 and acute myeloid leukemia: None of the EZH2-mut patients had a mutation in FLT3 or NPM1. In contrast, EZH2-wild-type (wt) AML patients had a median of 2 mutations, most frequently in DNMT3A (13/45, 29%), NRAS (10/45, 22%), NPM1 (9/45, 20%), FLT3, IDH1, TET2 (7/45 each, 16%), ASXL1, and TP53 (6/45 each, 13%).